-
15-09-2015, 04:19 PM
#4461
Blisfool
Originally Posted by Flugenbear
I'm picking a small loss but increased sales....
I'm picking $1.1M second quarter sales just on $2.1M for the first 6 months, with a loss because of added operating costs of keeping sales growth.
But a significant improvement on last years "Same Peiod" result. With commentary on continued sales growth and maybe a more confident prediction of a small profit at the end of march. Sales growth to head thru $5M fo the full year.
If every thing continues on the same trajectory 2016 will be a good calender year for Blis, there are a lot of trials finishing and results to be published, this will only fuel accelerated growth, especially in USA and China. Some countries in Europe have all ready accepted the product and consumer word of mouth should continue the growth there.
I am very interested to see what are the outcomes of the trail that is being done in NZ in Conjunction with the Cure Kids group.
Knowing Blis, the next announcement will not be boring
-
25-09-2015, 06:17 PM
#4462
Member
Originally Posted by blissfool
I'm picking $1.1M second quarter sales just on $2.1M for the first 6 months, with a loss because of added operating costs of keeping sales growth.
But a significant improvement on last years "Same Peiod" result. With commentary on continued sales growth and maybe a more confident prediction of a small profit at the end of march. Sales growth to head thru $5M fo the full year.
If every thing continues on the same trajectory 2016 will be a good calender year for Blis, there are a lot of trials finishing and results to be published, this will only fuel accelerated growth, especially in USA and China. Some countries in Europe have all ready accepted the product and consumer word of mouth should continue the growth there.
I am very interested to see what are the outcomes of the trail that is being done in NZ in Conjunction with the Cure Kids group.
Knowing Blis, the next announcement will not be boring
Interest has been slowly building with this stock.....looking to take a position ahead of there results next month..
-
30-09-2015, 02:37 PM
#4463
Interesting that despite all the general negativity in the market BLT has risen 33% over the past month to 2.4 cents this morning.
Mr Market must be anticipating a much improved result for the half-year, though I think we'll have to wait until early November for the announcement.
I'm picking that he might just be right this time around. Onwards and upwards finally for BLT...maybe.
-
05-10-2015, 02:13 PM
#4464
Interesting news from BLT. Only a small trial but great results
Ear Infections Reduced Through Use Of Blis K12 - Italian Clinical Study
The International Journal of General Medicine reports findings of an Italian
clinical study showing the daily use of BLIS K12 reduced the rate of ear
infections (acute otitis media) by over 40% when compared to diagnosed
infections from the same populations in the prior 12 months.
In addition, there was a 50-60% improvement in specific measurements for
hearing (p<0.01) as well as an approximate 40% improvement in the appearance
of the ear canal and eardrum (p<0.05), including reductions in fluid build-up
in the middle ear.
Those latest results confirm and extend earlier findings in both children and
adults, establishing the importance of a healthy oral cavity microbiome and
demonstrating the striking benefits of daily BLIS K12 supplementation in
promoting oral health.
The results of this study also reconfirm the excellent safety profile of BLIS
K12 in children with no adverse effects reported.
In this pilot study, conducted by a Milan-based research team, 22 children
ages 3-9 years old with a recent history of acute otitis media and fluid in
one or both ears for at least two months were selected for participation in
the study. They were each administered a once daily chewable lozenge
containing BLIS K12.
Middle ear infections are common in children affecting 80% of children at
some time during their childhood. Acute otitis media can become a lingering
problem resulting in an inflammatory condition characterised by persistent
fluid in the middle ear cavity. If left untreated it can lead to
hearing-related complications.
NZX-listed Blis Technologies chief executive Barry Richardson said the latest
trial followed three previous successful trials by the same Italian group.
One of those previous trials using BLIS K12 on strep throat indicated a
secondary effect of reduction of ear infections so this trial follows up that
observation.
Blis Technologies commercialised the BLIS K12 strain of Streptococcus
salivarius that has resulted from research carried out at the University of
Otago by Professor John Tagg.
END
"Don't be afraid to take a big step if one is indicated. You can't cross a chasm in two small jumps." David Lloyd George
-
14-10-2015, 05:07 PM
#4465
Originally Posted by pierre
Interesting that despite all the general negativity in the market BLT has risen 33% over the past month to 2.4 cents this morning.
Mr Market must be anticipating a much improved result for the half-year, though I think we'll have to wait until early November for the announcement.
I'm picking that he might just be right this time around. Onwards and upwards finally for BLT...maybe.
I got the timing wrong (in a positive sense) but looks like my hunch was right. A profit at last. Great work from the BLT team - definitely onwards and upwards from hereon!
Record Sales and Revised Guidance
Blis Technologies reports that record sales of finished goods in August and
September has resulted in revenue of $2.7m for the September 2015 half year
an increase of 139% over the corresponding September 2014 period. As a
consequence Blis Technologies expects to table a modest surplus in earnings
before interest tax depreciation and amortisation and a small loss for the
period when it presents its full half year financial results in late
November.
Based on the expected half year results, forward orders, planned customer
product releases and the prevailing exchange rate Blis Technologies has
further revised its guidance for the full year for revenue to increase by
over 100% year on year to in excess of $5.3m. Consequently expectations for
the full year are now for a surplus in earnings before interest tax
depreciation and amortisation.
"Don't be afraid to take a big step if one is indicated. You can't cross a chasm in two small jumps." David Lloyd George
-
14-10-2015, 05:08 PM
#4466
Today's news is great news for holders……
Blis Technologies reports that record sales of finished goods in August and |
September has resulted in revenue of $2.7m for the September 2015 half year |
an increase of 139% over the corresponding September 2014 period. As a |
consequence Blis Technologies expects to table a modest surplus in earnings |
before interest tax depreciation and amortisation and a small loss for the |
period when it presents its full half year financial results in late |
November. |
|
Based on the expected half year results, forward orders, planned customer |
product releases and the prevailing exchange rate Blis Technologies has |
further revised its guidance for the full year for revenue to increase by |
over 100% year on year to in excess of $5.3m. Consequently expectations for |
the full year are now for a surplus in earnings before interest tax |
depreciation and amortisation. |
-
14-10-2015, 05:16 PM
#4467
-
14-10-2015, 05:34 PM
#4468
Member
Originally Posted by simla
Wow and Corker!
Looks to be a good solid result. Looking forward to the full report!
-
14-10-2015, 06:56 PM
#4469
Member
-
14-10-2015, 08:20 PM
#4470
Blisfool
Originally Posted by simla
Wow and Corker!
That was a huge surprise an outstanding result, it will be interesting to see which country the growth came from. Blis is definately on the right track.
With more population in northern hempishere markets about to start going thru winter the sales results for the next 6 months could be huge. With the alot of trials and tests due next year, 2016 will be a very good calender year for Blis. Alot of media talk about the prevention of Rheumatic fever hopefully one of these studies provides a strong link between taking Blis and reducing the risk of this hideous disease.
Congrats to the team at Blis
Tags for this Thread
Posting Permissions
- You may not post new threads
- You may not post replies
- You may not post attachments
- You may not edit your posts
-
Forum Rules
|
|
Bookmarks